Please login to the form below

Not currently logged in
Email:
Password:

Immunocore

This page shows the latest Immunocore news and features for those working in and with pharma, biotech and healthcare.

Cancer disruptor F Star names next CEO

Cancer disruptor F Star names next CEO

He is now handing over to Forster, who recently left another UK biotech, Oxford-based Immunocore. ... While Immunocore is focused on novel immuno-oncology drugs, F-star specialises a new generation of bispecific antibodies, with cancer also its prime

Latest news

  • Christina Coughlin to leave Immunocore for Tmunity Christina Coughlin to leave Immunocore for Tmunity

    Christina Coughlin to leave Immunocore for Tmunity. UPenn pioneers building their own biotech company. ... The departure of Coughlin will be another loss for Immunocore, meanwhile, as it CEO Eliot Forster left the company in February.

  • UK biotech beats fundraising records in 2015, says BIA UK biotech beats fundraising records in 2015, says BIA

    BIA chief executive Steve Bates pointed to examples such as Immunocore's record-breaking £205m round as evidence of a growing maturity in the UK sector as it strives to become

  • Lilly and AZ forge closer immuno-oncology bond Lilly and AZ forge closer immuno-oncology bond

    It also has an alliance with Immunocore that will combine gulisertib and Lilly's multi-kinase inhibitor merestinib with Immunocore's small-molecule TCR-targeting drugs.

  • Celgene and Juno announce ten-year cancer deal Celgene and Juno announce ten-year cancer deal

    This comes in the same week that Lilly announced a similar deal with UK-based Immunocore to test the biotech's lead T-cell receptor based investigational therapeutic IMCgp100, in combination ... This means that any drug approval from the Lilly/Immunocore

  • Lilly and Immunocore ink immunotherapy R&D deal Lilly and Immunocore ink immunotherapy R&D deal

    Lilly and Immunocore ink immunotherapy R&D deal. Firms will test new joint therapy in patients with melanoma. ... This means that any drug approval from the Lilly/Immunocore collaboration will likely be late to the market.

More from news
Approximately 7 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare (part 2)

    Officer at Immunocore (since 2013), one of the most hotly-tipped UK biotech companies in the field of immunotherapy. ... and GlaxoSmithKline have each signed significant strategic discovery deals during Eva-Lotta’s five years at Immunocore.

  • Pharma deals in July 2015 Pharma deals in July 2015

    This month, Immunocore which develops T-cell receptor based drugs and has a lead product in Phase IIa, raised $320m (£205m) via a private financing round from a syndicate of investors, ... It is hoped that Immunocore and Mereo are signs that at long

  • Pharma deals in March 2015 Pharma deals in March 2015

    Sir John Bell, Regius Professor of Medicine at Oxford University and a non-executive director of Immunocore has criticised the City of London for failing to provide financial support to life

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    30. Immunocore/ Eli Lilly. Co-discovery /co-development, options (cost/profit share). ImmTAC (Immune mobilising mTCR Against Cancer) technology (discovery).

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    Other deals include an alliance with the UK biotech Immunocore via AZ's MedImmune subsidiary and an expansion of an existing personalised drug partnership with Horizon Discovery. “

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • Industry appointments Industry appointments

    Most recently, Hassan built the oncology-focused biology, preclinical and biomarker units for Immunocore, overseeing early development and the first-in-human trial of a TCR based biologic targeting a melanoma

  • Immunocore appoints chief financial officer Immunocore appoints chief financial officer

    Oxford, UK-based Immunocore has appointed Paul Fry as its chief financial officer. ... As Immunocore continues to grow we are continually looking for outstanding individuals such as Paul to complement our team.

  • Immunocore names CEO Immunocore names CEO

    The UK-based biotech Immunocore has appointed industry veteran Dr Eliot Forster as CEO. ... His significant drug development experience will be invaluable to Immunocore as we continue to deliver within our partnerships and advance our proprietary ImmTAC

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics